The Committee for Medicinal Products for Human Use recommended approval of Kapruvia as the first therapy in Europe for chronic kidney disease-associated pruritus in patients on hemodialysis, according to a release.
Kapruvia (difelikefalin) will be the first therapy of its kind available in Europe if it gains European Union marketing authorization, according to the release. Vifor Fresenius Medical Care Renal Pharma partnered with Cara Therapeutics Inc. on the treatment and await a final decision from the European Commission in the second quarter of 2022.
“The positive Committee for